Litigation Details for H. Lundbeck A/S v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)

« Back to Dashboard

H. Lundbeck A/S v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)

Docket		Date Filed	2018-01-25
Court	District Court, D. Delaware	Date Terminated	2021-10-29
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,144,884; 8,476,279; 8,722,684; 8,969,355; 9,227,946; 9,861,630
Link to Docket	External link to docket

Details for H. Lundbeck A/S v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-25				External link to document
2018-01-24	12		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,861,630 B1; . (Noreika, Maryellen… 25 January 2018 1:18-cv-00150 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-01-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,144,884 B2; 8,476,279 B2; 8,722,684…2018 29 October 2021 1:18-cv-00150 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Executive summary H. Lundbeck A/S v. Zydus Pharmaceuticals (USA) Inc., No. 1:18-cv-00150, is a Hatch-Waxman patent infringement dispute tied to Zydus’s FDA ANDA for an H. Lundbeck product. The record in the public case docket supports a Section 271(e)(2) claim framework (ANDA acts as the infringing trigger). The litigation’s business impact is driven by (i) which Orange Book-listed patents were asserted, (ii) whether the parties reached a consent judgment or dismissal after an ANDA settlement, and (iii) the timing of any design-around development or generic launch shift.

H. Lundbeck A/S v. Zydus Pharmaceuticals (USA) Inc. (1:18-cv-00150): what is the case about? Answer: This is a generic patent infringement case under 35 U.S.C. § 271(e)(2) based on an ANDA filing by Zydus and asserted patents owned or controlled by H. Lundbeck A/S.

What does the docket posture indicate?

The case number format (1:18-cv-00150) and the defendant naming indicate a federal district court Hatch-Waxman action in which:

• The ANDA filing date is the anchor event for “artificial infringement” under §271(e)(2).
• Lundbeck asserts one or more Orange Book patents covering the approved drug, typically including composition, method-of-use, and/or formulation/processing-related patents.
• The defendant typically responds with non-infringement, invalidity, and sometimes non-infringement-by-design-around positions.

Who are the parties and what roles do they play?

• Plaintiff: H. Lundbeck A/S (patent owner and brand-side litigant).
• Defendant: Zydus Pharmaceuticals (USA) Inc. (ANDA applicant and generic-side defendant).

What product area is most likely implicated?

Lundbeck’s US patent estate most frequently centers on CNS and neurology brands, including antidepressants and related compounds, with frequent litigation over polymorph, salts, methods of treatment, and controlled-release formulations. The docket alone does not identify the asserted product in a way that can be stated definitively without the asserted-patent list and complaint particulars.

H. Lundbeck v. Zydus (1:18-cv-00150): what patents were asserted? Answer: The asserted patents and their Orange Book numbers drive the scope. A complete and accurate listing of asserted patents cannot be produced from the information provided in the query alone.

Patent-specific questions that matter for valuation

• Which patent families were asserted (composition vs formulation vs method-of-use)?
• Were the asserted patents listed in the Orange Book for the relevant NDA/BLA at the time of the ANDA?
• Did Lundbeck plead multiple patents in the same case to cover different claim types:
  • composition and polymorph
  • process/manufacturing method
  • formulation or dissolution profile
  • method-of-use or dosing regimen

How to map the asserted portfolio to infringement theories

Hatch-Waxman cases usually break into:

• Infringement by the ANDA product as claimed in the ANDA ANDA-label and proposed manufacturing description
• Invalidity arguments:
  • anticipation/obviousness (prior art and obviousness combinations)
  • lack of written description or enablement
  • indefiniteness for claim clarity

A credible summary requires the actual asserted patent numbers and the specific claim themes Lundbeck alleged.

H. Lundbeck v. Zydus (1:18-cv-00150): what was the litigation timeline and key procedural events? Answer: The case was filed in 2018 and proceeds on an ANDA-driven schedule typical for Hatch-Waxman litigation, where the court’s milestones track discovery, expert reports, and claim construction, with expedited schedules keyed to the “30-month stay” regime.

What timeline checkpoints are standard in this posture?

• Complaint and service (triggers automatic procedural deadlines).
• Responsive pleadings and initial invalidity/non-infringement positions.
• Markman/claim construction briefing and hearing.
• Expert disclosures (technical chemistry/formulation and legal claim interpretation).
• Summary judgment and trial (if not resolved earlier).
• Possible settlement or consent judgment resolution near or after claim construction.

What the outcome category typically is

Without the docket events (orders, stipulations, or judgment), outcomes fall into three business-relevant bins:

1. Judgment for generic (no infringement and/or patents invalid)
2. Judgment for brand (infringement and patents enforceable)
3. Settlement (often with dates of generic launch and/or covenant not to sue)

H. Lundbeck v. Zydus (1:18-cv-00150): did the case settle, and what does that mean for generic launch risk? Answer: The settlement status cannot be determined from the information provided, so the presence or absence of a consent judgment, stipulated dismissal, or settlement-driven launch date cannot be stated accurately.

What an ANDA settlement typically changes

If settled, the agreement usually:

• Fixes a “launch date” window (carve-outs for additional strengths/dosage forms)
• Provides a covenant not to sue on asserted patents (sometimes for a limited product configuration)
• Allocates any remaining contingent issues (injunction scope, damages exposure, or future patent continuation)

From a licensing and litigation strategy perspective, the key question is whether settlement was tied to:

• an “at-risk” launch date
• a design-around that avoids specific claim limitations
• dismissal with prejudice (full case termination) or dismissal without prejudice (rare in the key Hatch-Waxman commercial sense)

H. Lundbeck v. Zydus (1:18-cv-00150): what were the legal positions on non-infringement and invalidity? Answer: A complete litigation analysis requires the complaint’s asserted claim mapping and the defendant’s invalidity theories (reference patents and publications, plus claim charts). That detail is not provided in the query.

Typical Lundbeck legal positions in Lundbeck-led ANDA suits

Brand-side positions often include:

• Composition/formulation claim coverage based on the generic’s ANDA product identity (API form, salt, polymorph).
• Dissolution profile equivalence that maps to formulation limitations.
• Method-of-use coverage based on label indications and dosing regimen.

Typical Zydus legal positions in this procedural posture

Generic defendants often argue:

• Non-infringement by design-around:
  • different polymorph/salt form
  • different excipient system or manufacturing step
  • different release profile not meeting claim limitations
• Invalidity via:
  • prior art anticipation
  • obviousness
  • lack of adequate written description

Claim-construction as a practical driver

Claim construction frequently decides:

• whether “polymorph” limitations narrow to a specific lattice form or a broader characterization
• whether dissolution/delivery limitations require meeting numeric thresholds
• whether method-of-use claims are enforceable post-label approval for a Paragraph IV ANDA

Without the actual claim terms asserted, any “analysis” would be speculative.

H. Lundbeck v. Zydus (1:18-cv-00150): how does this affect FDA ANDA exclusivity and Orange Book status? Answer: The exclusivity impact depends on which Orange Book patents were asserted and whether the case resulted in a stay, injunction, or settlement launch date. Those specifics are not in the prompt, so the Orange Book effect cannot be stated accurately.

What matters for exclusivity sequencing

• Patent exclusivity does not equal 30-month stay. The stay is tied to Paragraph IV notice and litigation timing.
• If patents were asserted and the case proceeded to judgment, the relevant effect is:
  • injunction preventing FDA approval for the generic until resolution
  • court dismissal/stipulation that can unlock approval
• If settlement was reached, the “launch date” is usually the controlling commercial parameter.

Orange Book listings to track in practice

For dossier and competitive planning, track:

• Patent numbers, expiration dates, and statutory basis
• Listed drug product (NDA, strength, dosage form)
• Patent type (drug substance, drug product, method of use)
• Status indicators (active, expired, withdrawn)

H. Lundbeck v. Zydus (1:18-cv-00150): what generic entry risks existed for Zydus? Answer: The generic entry risk is structurally high at filing because an ANDA Paragraph IV triggers the 30-month stay if the litigation is timely and qualifies. Whether Zydus’s risk materialized into an injunction or a design-around path depends on the outcome.

Risk drivers

• Court likelihood of construing claims narrowly in generic’s favor
• Validity vulnerabilities:
  • if Lundbeck patents were earlier filed and later claimed broader subject matter, written description and enablement can be tested
• Evidence:
  • formulation comparisons
  • ANDA manufacturing details and impurity profile correlations

How strong is Lundbeck’s patent estate in cases like 1:18-cv-00150? Answer: “Strength” is case-specific and claim-specific. The absence of the asserted patent list in the query prevents a rigorous estate-quality evaluation for this dispute.

How to evaluate strength in an investable way

For each asserted patent family, you would score:

• Remaining term (expiration and any terminal disclaimers)
• Claim breadth vs specificity
• Claim-construction likelihood
• Prior litigation outcomes in the same family
• Off-target prior art exposure

This framework cannot be populated without asserted patents and their bibliographic details.

Key litigation takeaways for business action

Last updated: July 13, 2026

• The case is a Hatch-Waxman ANDA infringement action under §271(e)(2), with outcome determinative for generic launch timing and market entry.
• Commercial exposure depends on which Orange Book patents were asserted and whether the parties resolved via judgment or settlement.
• A full litigation summary and portfolio analysis requires the asserted patent numbers and the procedural outcome records, which are not included in the provided prompt.

---

Key Takeaways

• 1:18-cv-00150 is structured as a Paragraph IV-style ANDA patent dispute with brand-side claims under §271(e)(2).
• The patent list and final procedural outcome are the only elements that can credibly drive launch timing and licensing/settlement valuation.
• Those critical docket details are not present in the provided input, so a complete, accurate litigation analysis cannot be produced.

FAQs

1) What does a “1:18-cv-00150” Hatch-Waxman case number imply for the procedural schedule?
It indicates a federal district court case where an ANDA Paragraph IV dispute typically proceeds on an expedited track with milestones for claim construction and merits.

2) Does an ANDA settlement in a Lundbeck case always guarantee generic approval on the launch date?
It depends on the exact settlement terms, including any covenants, carve-outs, and whether approval is linked to dismissals and FDA regulatory events.

3) How do method-of-use versus formulation patents change litigation strategy?
Method-of-use disputes focus on label-induced infringement and dosing regimen proof, while formulation disputes focus on composition, polymorph/salt form, and dissolution/release limitations.

4) What evidence most often drives claim construction in formulation polymorph cases?
Intrinsic evidence in the patents and expert testimony on how a skilled artisan would interpret polymorph/dissolution/release claim terms.

5) What is the practical difference between a judgment of non-infringement and an invalidity ruling for follow-on ANDAs?
Invalidity can clear the way for other generic entrants more broadly on the same patent claims, while non-infringement can still leave design-around-specific constraints.

---

References

No sources were provided in the prompt, and no asserted-patent docket specifics were included; therefore no citations can be accurately listed.